Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,378 across all filing types
Latest filing 2019-10-17 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
PUBLICATION OF THE PRODUCTION AND SALES VOLUME FOR THE THIRD QUARTER OF 2019 OF AN OVERSEAS SUBSIDIARY CONTROLLED BY YANZHOU COAL MINING COMPANY LIMITED
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Yanzhou Coal Mining Company Limited regarding the production and sales volume for the third quarter of 2019 of an overseas subsidiary, Yancoal Australia. It provides specific quarterly production and sales data but does not contain comprehensive financial statements or detailed financial analysis. The document is relatively short (2496 characters) and refers readers to the full reports published by Yancoal Australia on the ASX and HKEX websites for further details. This indicates that the document is an announcement of operational data rather than a full interim or quarterly financial report. Therefore, it does not meet the criteria for an Interim/Quarterly Report (IR) which requires substantive financial data and analysis. Instead, it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement providing operational updates without full financial statements or detailed analysis.
2019-10-17 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' for a Main Board listed issuer, CStone Pharmaceuticals, and details changes in issued share capital and share buybacks. It includes specific data on share issues pursuant to employee share option exercises and confirms compliance with listing rules. The document also contains a purchase report section related to share repurchases. The content focuses on disclosures of share capital changes and share buybacks, which aligns with announcements regarding share issues and capital changes. There is no indication that this is a full financial report, audit, or earnings release. The detailed disclosure of share issuance and repurchase activities fits the definition of a Share Issue/Capital Change announcement rather than a full report or other categories. The document length (10,570 characters) and detailed data confirm it is not a brief announcement or a report publication notice. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2019-10-15 English
GRANT OF SHARE OPTIONS
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from CStone Pharmaceuticals regarding the grant of share options to employees under the Post-IPO ESOP. It details the number of options granted, subscription price, vesting schedule, and the purpose of the grant. The document is a regulatory announcement about a share option grant, which is a capital-related event but not a full report or financial statement. It is not an annual or interim report, earnings release, or management discussion. It is also not a director dealing report since it explicitly states no options were granted to directors or substantial shareholders. The document fits best under the category of Share Issue/Capital Change (SHA) as it announces a new share option grant affecting the company's capital structure. The document length is over 6,000 characters and contains detailed information about the grant, not just a brief notice or report publication announcement. Therefore, the classification is SHA with high confidence.
2019-10-13 English
NOTIFICATION OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a notification of a board meeting scheduled to consider the publication of the company's unaudited third quarterly results. It is an announcement about an upcoming event rather than the actual financial report or detailed financial data. The document length is short (1654 characters), and it does not contain financial statements or substantive financial analysis. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) as a general announcement about the board meeting and upcoming results publication.
2019-10-11 English
Notification Letter
Report Publication Announcement Classification · 95% confidence The document is a notification letter from Yanzhou Coal Mining Company Limited dated 11 October 2019. It informs shareholders about the publication of the circular for the 2019 Second Extraordinary General Meeting and provides instructions on how shareholders can access the circular electronically or request printed copies. It also includes a Change Request Form for shareholders to update their preferences for receiving corporate communications. The document does not contain the circular itself or any substantive financial data or analysis. It is essentially an announcement about the availability of a corporate communication document and instructions related to it. Therefore, this document is best classified as a Report Publication Announcement (RPA), which covers announcements regarding the timing, release, or publication of company reports or communications.
2019-10-11 English
Circular
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular from Yanzhou Coal Mining Company Limited to its shareholders regarding an Extraordinary General Meeting (EGM) scheduled for November 1, 2019. The circular includes detailed information about the agenda items for the EGM, specifically the 2019 Interim Profit Distribution Plan and a major continuing connected transaction involving financial services. It contains definitions, letters from the board, independent board committee, and independent financial adviser, as well as appendices with financial and general information. The document is not a financial report itself but a solicitation and information statement to shareholders to inform them and seek their approval on specific proposals at the EGM. This matches the description of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document is lengthy (15,000 characters) and contains substantive content aimed at informing shareholders for voting decisions, not just an announcement or notice. Therefore, the appropriate classification is PSI.
2019-10-11 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.